EP2049096A4 - Method of treating chronic myelogenous leukemia cells - Google Patents

Method of treating chronic myelogenous leukemia cells

Info

Publication number
EP2049096A4
EP2049096A4 EP07813692A EP07813692A EP2049096A4 EP 2049096 A4 EP2049096 A4 EP 2049096A4 EP 07813692 A EP07813692 A EP 07813692A EP 07813692 A EP07813692 A EP 07813692A EP 2049096 A4 EP2049096 A4 EP 2049096A4
Authority
EP
European Patent Office
Prior art keywords
myelogenous leukemia
chronic myelogenous
leukemia cells
treating chronic
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07813692A
Other languages
German (de)
French (fr)
Other versions
EP2049096A2 (en
Inventor
Kapil N Bhalla
Francis Y Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
Bristol Myers Squibb Co
Original Assignee
University of South Florida
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida, Bristol Myers Squibb Co filed Critical University of South Florida
Publication of EP2049096A2 publication Critical patent/EP2049096A2/en
Publication of EP2049096A4 publication Critical patent/EP2049096A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07813692A 2006-08-02 2007-08-02 Method of treating chronic myelogenous leukemia cells Withdrawn EP2049096A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82118406P 2006-08-02 2006-08-02
PCT/US2007/075061 WO2008017024A2 (en) 2006-08-02 2007-08-02 Method of treating chronic myelogenous leukemia cells

Publications (2)

Publication Number Publication Date
EP2049096A2 EP2049096A2 (en) 2009-04-22
EP2049096A4 true EP2049096A4 (en) 2012-05-09

Family

ID=38997865

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07813692A Withdrawn EP2049096A4 (en) 2006-08-02 2007-08-02 Method of treating chronic myelogenous leukemia cells

Country Status (3)

Country Link
US (1) US7799788B2 (en)
EP (1) EP2049096A4 (en)
WO (1) WO2008017024A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7861014B2 (en) * 2007-08-31 2010-12-28 International Business Machines Corporation System for supporting partial cache line read operations to a memory module to reduce read data traffic on a memory channel
WO2009108755A2 (en) * 2008-02-27 2009-09-03 Wyeth Pharmaceutical combinations for the treatment of cancer
EP3143166A4 (en) * 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177223B9 (en) * 2001-09-05 2012-10-31 Ivax International Gmbh Homoharringtonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to protein kinase inhibitors other than STI 571
US20030147813A1 (en) * 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 204A, ISSN: 0006-4971 *
BRADEEN HEATHER A ET AL: "COMPARISON OF IMATINIB, MESYLATE, DASATINIB (BMS-354825), AND NILOTINIB (AMN107) IN AN N-ETHYL-N-NITROSOUREA (ENU)-BASED MUTAGENESIS SCREEN: HIGH EFFICACY OF DRUG COMBINATIONS", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 7, 1 October 2006 (2006-10-01), pages 2332 - 2338, XP009082064, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2006-02-004580 *
DAI YUN ET AL: "Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.", MOLECULAR AND CELLULAR BIOLOGY JUL 2005 LNKD- PUBMED:15964800, vol. 25, no. 13, July 2005 (2005-07-01), pages 5429 - 5444, XP002672184, ISSN: 0270-7306 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), SKAGGS BRIAN J ET AL: "Altered oncogenic fitness of imatinib- and dasatinib-resistant BCR-ABL mutants is due to differential intrinsic kinase activity and signaling pathway selection defined by phosphoproteome profiling.", XP002672183, Database accession no. PREV200600183062 *
FISKUS W ET AL: "Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 2, 15 July 2006 (2006-07-15), pages 645 - 652, XP008131474, ISSN: 0006-4971, [retrieved on 20060314], DOI: 10.1182/BLOOD-2005-11-4639 *
FISKUS W ET AL: "Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells", CLINICAL CANCER RESEARCH 20061001 US LNKD- DOI:10.1158/1078-0432.CCR-06-0980, vol. 12, no. 19, 1 October 2006 (2006-10-01), pages 5869 - 5878, XP002672182, ISSN: 1078-0432 *
KELLY W K ET AL: "HISTONE DEACETYLASE INHIBITORS: FROM TARGET TO CLINICAL TRIALS", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 11, no. 12, 1 December 2002 (2002-12-01), pages 1695 - 1713, XP001202636, ISSN: 1354-3784, DOI: 10.1517/13543784.11.12.1695 *
MANLEY ET AL: "Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, NETHERLANDS, vol. 1754, no. 1-2, 30 December 2005 (2005-12-30), pages 3 - 13, XP005214189, ISSN: 1570-9639, DOI: 10.1016/J.BBAPAP.2005.07.040 *
NIMMANAPALLI R ET AL: "Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 101, no. 8, 15 April 2003 (2003-04-15), pages 3236 - 3239, XP002263976, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2002-08-2675 *
THOMAS O'HARE ET AL: "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 65, no. 11, 1 June 2005 (2005-06-01), pages 4500 - 4505, XP002626481, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-0259 *
TOKARSKI JOHN S ET AL: "The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 66, no. 11, 1 June 2006 (2006-06-01), pages 5790 - 5797, XP002431105, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-4187 *

Also Published As

Publication number Publication date
EP2049096A2 (en) 2009-04-22
US20090215792A1 (en) 2009-08-27
WO2008017024A2 (en) 2008-02-07
US7799788B2 (en) 2010-09-21
WO2008017024A3 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
IL257681A (en) Methods and compositions for treating cancer
IL257418A (en) Methods for treating dependence
HK1204277A1 (en) Compositions and methods for treating demodex infestations
EP2282741A4 (en) Treating eosinophilic esophagitis
EP2032131A4 (en) Method of treatment
EP1991230A4 (en) Methods of treating cancer
IL193099A0 (en) Method of treating chronic kidney disease
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
EP2124985A4 (en) Methods and compositions for treating neuropathies
IL197633A0 (en) Methods for treating cancer with mva
EP2174912A4 (en) Method of treating copper-arsenic compound
GB2455622B (en) Plunge milling method
EP2081437A4 (en) Methods for treating or preventing infestation
GB0610746D0 (en) Method of treatment
IL238394A0 (en) Cancer treatment method
EP2144888A4 (en) Methods for treating cancer
IL182618A0 (en) Methods and compositions for treating chronic lymphocytic leukemia
EP2086560A4 (en) Methods of treating epiphora
EP2088862A4 (en) Cancer treatment method
GB0718684D0 (en) Treatment method
EP2068911A4 (en) Methods for treating cancer
EP2216408A4 (en) Method for improving salinity tolerance
EP2049096A4 (en) Method of treating chronic myelogenous leukemia cells
EP1951238A4 (en) Method for treating chronic pain
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090216

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4745 20060101ALI20120326BHEP

Ipc: G01N 33/50 20060101ALI20120326BHEP

Ipc: A61P 35/02 20060101ALI20120326BHEP

Ipc: A61K 45/06 20060101ALI20120326BHEP

Ipc: A61K 31/506 20060101ALI20120326BHEP

Ipc: A61K 31/19 20060101AFI20120326BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120410

17Q First examination report despatched

Effective date: 20141021

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150303